• 1
    Lipshutz RJ, Fodor SP, Gingeras TR, Lockhart DJ. High density synthetic oligonucleotide arrays. Nat Genet. 1999; 21: 2024.
  • 2
    Haferlach T, Kohlmann A, Kern W, Hiddemann W, Schnittger S, Schoch C. Gene expression profiling as a tool for the diagnosis of acute leukemias. Semin Hematol. 2003; 40: 281295.
  • 3
    Grimwade D, Haferlach T. Gene-expression profiling in acute myeloid leukemia. N Engl J Med. 2004; 350: 16761678.
  • 4
    Staudt LM. Molecular diagnosis of the hematologic cancers. N Engl J Med. 2003; 348: 17771785.
  • 5
    Ebert BL, Golub TR. Genomic approaches to hematologic malignancies. Blood. 2004; 104: 923932.
  • 6
    Campana D, Behm FG. Immunophenotyping of leukemia. J Immunol Methods 2000; 243: 5975.
  • 7
    Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood. 2004; 104: 30783085.
  • 8
    Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood. 2001; 98: 2935.
  • 9
    Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 1998; 351: 550554.
  • 10
    Schoch C, Kohlmann A, Schnittger S, et al. Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci U S A. 2002; 99: 1000810013.
  • 11
    Kohlmann A, Schoch C, Schnittger S, et al. Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients. Leukemia. 2004; 18: 6371.
  • 12
    Kern W, Kohlmann A, Schoch C, et al. Gene expression profiling in adult acute lymphoblastic leukemia, biphenotypic acute leukemia, and acute myeloid leukemia without differentiation: confirmation of immunophenotypic and cytogenetic diagnostic findings. Blood. 2004; 104.
  • 13
    Haferlach T, Schnittger S, Kern W, Hiddemann W, Schoch C. Genetic classification of acute myeloid leukemia (AML). Ann Hematol. 2004; 83( Suppl 1): S97100.
  • 14
    Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403: 503511.
  • 15
    Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001; 194: 16391647.
  • 16
    Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002; 1: 133143.
  • 17
    Ross ME, Zhou X, Song G, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 2003; 102: 29512959.
  • 18
    Kohlmann A, Schoch C, Schnittger S, et al. Molecular characterization of acute leukemias by use of microarray technology. Genes Chromosomes Cancer. 2003; 37: 396405.
  • 19
    Ross ME, Mahfouz R, Onciu M, et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood. 2004; 104: 36793687.
  • 20
    Haferlach T, Kohlmann A, Schnittger S, et al. AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes. Genes Chromosomes Cancer. 2005; 43: 113127.
  • 21
    Haferlach T, Kohlmann A, Schnittger S, et al. A global approach to the diagnosis of leukemia using gene expression profiling. Blood. 2005; 106: 11891198.
  • 22
    Kohlmann A, Schoch C, Dugas M, et al. New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes. Leukemia. 2005; 19: 953964.
  • 23
    Kern W, Kohlmann A, Wuchter C, et al. Correlation of protein expression and gene expression in acute leukemia. Cytometry. 2003; 55B: 2936.
  • 24
    Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press, 2001.
  • 25
    Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995; 9: 17831786.
  • 26
    Haferlach T, Schoch C. Modern techniques in leukemia diagnosis. Internist. 2002; 43: 11901202.
  • 27
    Kern W, Voskova D, Schoch C, Schnittger S, Hiddemann W, Haferlach T. Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia. Haematologica. 2004; 89: 528540.
  • 28
    Hubbell E, Liu WM, Mei R. Robust estimators for expression analysis. Bioinformatics. 2002; 18: 15851592.
  • 29
    Moenner M, Vosoghi M, Ryazantsev S, Glitz DG. Ribonuclease inhibitor protein of human erythrocytes: characterization, loss of activity in response to oxidative stress, and association with Heinz bodies. Blood Cells Mol Dis. 1998; 24: 149164.
  • 30
    Chen G, Zeng W, Miyazato A, et al. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood. 2004; 104: 42104218.
  • 31
    Malec M, van der Velden VH, Bjorklund E, et al. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping. Leukemia. 2004; 18: 16301636.
  • 32
    Kern W, Schoch C, Haferlach T, Voskova D, Hiddemann W, Schnittger S. Complemental roles for multiparameter flow cytometry and quantitative RT-PCR for the quantification of minimal residual disease in patients with acute myeloid leukemia. Blood. 2003; 102.
  • 33
    Haferlach T, Schoch C, Loffler H, et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol. 2003; 21: 256265.
  • 34
    Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood. 2003; 102: 23952402.
  • 35
    Schoch C, Haferlach T, Kern W, et al. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia. 2003; 17: 461463.
  • 36
    Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia. 2004; 18: 120125.
  • 37
    Hoelzer D. Therapy and prognostic factors in adult acute lymphoblastic leukaemia. Baillieres Clin Haematol. 1994; 7: 299320.
  • 38
    Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004; 350: 15351548.
  • 39
    Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000; 343: 19101916.
  • 40
    Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002; 100: 5966.
  • 41
    Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood. 2003; 102: 27462755.
  • 42
    Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003; 348: 17641775.
  • 43
    Frohling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004; 22: 624633.
  • 44
    Kern W, Diem H, Haferlach T. Immunophenotyping in modern leukemia diagnostics. Dtsch Med Wochenschr. 2005; 130: 21529.
  • 45
    Bullinger L, Dohner K, Bair E, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med. 2004; 350: 16051616.
  • 46
    Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004; 350: 16171628.
  • 47
    Kohlmann A, Schoch C, Dugas M, et al. Pattern robustness of diagnostic gene expression signatures in leukemia. Genes Chromosomes Cancer. 2005; 42: 299307.
  • 48
    Kern W, Kohlmann A, Schnittger S, Hiddemann W, Schoch C, Haferlach T. Gene expression profiling as a diagnostic tool in acute myeloid leukemia. Am J Pharmacogenom. 2004; 4: 225237.